Trial Profile

Phase 2 Clinical trial of nivolumab in metastatic rare cancer with dMMR or MSI-H and relation with immune phenotypic analysis (the ROCK trial).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Extramammary Paget disease; Glioblastoma; Intestinal cancer; Leiomyosarcoma; Neuroendocrine carcinoma; Ovarian cancer; Peritoneal cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Solitary-fibrous-tumour
Focus Biomarker; Therapeutic Use
Acronyms the ROCK trial

Most Recent Events

04 Jun 2024 Integrated results (MASTER KEY sub-studies: ROCK and ROLL trial) confirming the clinical significance of dMMR/MSI-H as a predictive marker, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
16 Oct 2023 New trial record
11 Oct 2023 Status changed from not stated to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com